New blockbuster drugs will push multiple myeloma market to $22.4 billion by 2023; Report

30 October 2015

The global treatment market for multiple myeloma will rise in value from $8.9 billion in 2014 to an estimated $22.4 billion by 2023, representing an impressive compound annual growth rate (CAGR) of 11.2%, new research indicates.

According to research and consulting firm GlobalData’s latest report, this increase, which will occur across the eight major markets of the USA, France, Germany, Italy, Spain, UK, Japan, and urban China, will be boosted by increasing therapeutic options, including the introduction of two monoclonal antibodies (MAbs) with blockbuster potential, namely Empliciti (elotuzumab), from US pharma majors Bristol-Myers Squibb (NYSE: BMY) and AbbVie (NYSE: ABBV), and daratumumab, from Denmark-based biotech firm Genmab A/S (OMX: GEN) and Johnson & Johnson (NYSE: JNJ) Janssen unit during the forecast period.

Dan Roberts, GlobalData’s senior analyst covering oncology and hematology, says the patent expiries of a number of key treatments will pave the way for the new MAbs to have a major impact on the multiple myeloma therapeutics space by 2023.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK